Prevention and treatment of ischemic stroke in patients with atrial fibrillation by Arabadzhieva, Daniela
Scripta Scientifica Medica, vol. 45, No 3, 2013, pp. 7-15
Copyright © Medical University of Varna   7
REVIEWS
PREVENTION AND TREATMENT OF ISCHEMIC STROKE  
IN PATIENTS WITH ATRIAL FIBRILLATION
Daniela Arabadzhieva
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SOCIAL EPIDEMIOLOGY
Atrial fibrillation (AF) is the most common 
sustained arrhythmia encountered in clinical 
practice (4,35,39). AF is independently associated 
with a fivefold increased risk of ischemic stroke (IS). 
IS caused by AF is particularly severe and disabling 
and IS prevention is of rising significance nowadays 
(47), particularly in the elderly. AF presence leads 
to more severe initial neurological involvement, 
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longer hospitalization, greater disability and a lower 
probability of discharge to home (39).
Acute IS incidence rate is studied in Kurashiki 
City, Japan, between March 2009 and February 2010. 
Crude incidence rate for first-ever cerebral infarction 
per 100,000 residents is 108,8 (95% confidence 
interval, 99,4-118,1). Using the world population 
model, age-adjusted incidence rate is 38,4 (95% 
confidence interval, 26,3-50,5) (25).
The Argentinean National Stroke Registry 
prospective, country-wide, hospital-based study 
demonstrates that 39,5% of 726 acute IS patients are 
unemployed. In-hospital mortality is higher in these 
patients than those who are employed (12,0% versus 
5,0%; p=0,003). On multivariate analysis, being 
unemployed (p=0,005), IS severity (p=0,018), and 
infarction size >15 mm (p=0,019) are related to higher 
in-hospital mortality rate indicating that social factors 
influence on poor outcomes after IS (44).
ABSTRACT
Atrial fibrillation (AF) is the most common sustained arrhythmia. It affects a considerable number of pa-
tients in the world and is responsible for ischemic stroke (IS) in many of them. Age greater than 75 years, 
congestive heart failure, arterial hypertension, diabetes mellitus, tobacco smoking and other structural le-
sions of the heart represent the main risk factors for IS in AF patients. Long-term anticoagulation thera-
py with warfarin is considered the most effective therapy for IS prevention in selected patients with AF and 
other risk factors. However, management of the drug presents with some challenges such as need for fre-
quent monitoring, interactions with food and other medications, variability in metabolism and delayed on-
set of action. Antiplatelet therapy may provide some benefit for patients who can’t tolerate warfarin. Re-
cently, direct oral thrombin inhibitor dabigatran and oral factor Xa inhibitors rivaroxaban and apixaban 
are approved by the Food and Drug Administration (FDA. Non-pharmacologic approaches to IS prevention 
in AF focus on occlusion or ligation of the left atrial appendage, which is often the location of thrombus for-
mation and on percutaneous techniques that may not require anticoagulation afterwards as well. New di-
agnostic modalities detect paroxysmal AF and expand the potential impact of preventive strategies on the 
population. 
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PATHOPHYSIOLOGICAL 
MECHANISMS OF AF
AF causes IS by thrombus formation in the left 
atrial appendage (LAA) and subsequent embolism to 
the brain. There is a link between AF and endothelial 
dysfunction explaining the relationship between AF, 
cardiovascular risk factors and IS (24). Endothelial 
dysfunction is a maladaptive state of endothelial 
cells, characterized by a constellation of impaired 
physiologic responses including: poor regulation 
of arterial tone, increased proinflammatory and 
prothrombotic mediators, overexpression of adhesion 
molecules and impaired endothelium-dependent 
vasodilation (24). Experimental AF is associated 
with these features and additionally enhanced 
platelet activation (24). Endothelial dysfunction 
can be particularly relevant in patients with other 
underlying disorders, such as arterial hypertension 
and diabetes mellitus, and offers some explanation 
as to why AF patients without other risk factors (i. e. 
those with ‘lone AF’) have a low risk of IS. Levels of 
von Willebrand’s factor are used in risk stratification 
for AF patients and are an independent risk factor for 
adverse events in them (37).
RISK FACTORS AND PROGNOSIS
Major risk factors for IS in the setting of AF 
include age greater than 75 years, congestive heart 
failure, arterial hypertension (AH), diabetes mellitus, 
tobacco smoking and other structural lesions of the 
heart (38). 
The analysis of 612 IS Japanese patients (293 with 
lacunar infarctions, 107 with large-artery occlusive 
infarctions, and 168 with embolic infarctions) 
indicates excess risk of IS in men with serum total 
cholesterol levels of ≥6,21 mmol/L than in those with 
the lowest category (<4,65 mmol/L). Multivariate 
hazard ratios and 95% confidence intervals are 1,63 
(1,14-2,35) for men and 1,03 (0,69-1,55) for women 
but concerning large-artery occlusive infarction, 
they are 2,86 (1,31-6,27) for men and 0,75 (0,28-2,01) 
for women, respectively (14).
The patients with prior IS or transient ischemic 
attack (TIA) and AF face the highest risk, more than 
twice that of AF patients without such a history. 
These factors are incorporated into risk stratification 
tools such as the commonly used CHADS2 
score (C=congestive heart failure, H=history of 
hypertension, A=age ≥75 years, D=diabetes, S=prior 
stroke or TIA). IS or prior TIA is assigned 2 points, 
while the other risk factors count for 1 point each. 
This 0- to 6-point scale can be used to quantify the 
patient’s risk of IS and thus guide decision making 
regarding the need for anticoagulation. This system 
is a widely used system for estimating the risk of IS 
in AF patients As a CHADS2 score of 2 is accepted 
as the level at which anticoagulation should be 
administered, any patient with a history of IS or TIA 
automatically reaches this threshold. More modest 
risk factors include female gender and presence 
of coronary artery disease or peripheral vascular 
disease (29). 
IS severity is assessed in 298 patients with AF-
related IS using National Institutes of Health Stroke 
Scale (NIHSS) and modified Rankin Scale scores ‘at 
discharge’ instead of the more common time of three 
months after onset (26). A high-risk CHADS2 score at 
admission is a powerful predictor of poor neurological 
outcome after controlling for all possible confounders 
and thus an independent predictor of all causes of 
death during the follow-up (26). Recently, however, 
neurological scores at discharge sufficiently represent 
the final neurological outcome of patients (8).
Additional risk factors include 
echocardiographic findings of complex aortic 
plaque or functional left atrial abnormalities. Age 
is a critical risk factor, too. Some additional factors 
are included in the scoring system CHA2DS2-VASc 
which considers the presence of vascular disease (V), 
age between 65 and 74 years (A) and female gender 
(Sc) (37). This expanded scoring system is most 
useful at risk-stratifying those patients at the lower 
end of CHADS2 spectra (48). 
The relationship between AF episode duration 
and the risk of IS is of great interest. Though 
paroxysmal and persistent AF have similar IS risks, 
there is no clear threshold for the AF duration 
necessary to form a thrombus in the left atrium (38). 
A period of 48 hours is accepted as the period before 
which cardioversion can be performed without the 
need for prior anticoagulation or transesophageal 
echocardiography (TEE). However, studies of 
patients being continually monitored via their 
implanted cardiac rhythm management devices 
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such as pacemakers and defibrillators render this 
threshold questionable.
Pacemaker patients at low risk (CHADS2=0) 
have a low risk of IS regardless of their AF burden 
(9) while patients at a high risk (CHADS2≥3) have a 
high risk of IS even with no documented AF. For the 
intermediate-risk group, the risk of IS depends on the 
patient’s AF burden as patients with more AF have an 
increased risk of IS. The comparison of traditional 
methods of monitoring patients for AF episodes with 
recordings from the implanted devices shows that 
occasional Holter monitoring typically done to assess 
AF burden is of low sensitivity and poor negative 
predictive value (9). The uncertainty surrounding 
the minimum AF duration needed to cause IS raises 
important questions as to the appropriate threshold 
for anticoagulation therapy in patients in whom the 
duration of AF can be reliably measured.
Current IS and bleeding risk scoring schemes 
in AF patients are based on complex scoring systems 
including similar risk factors which could confuse 
clinical decision making to balance these two risks and 
limits the applicability of these schemes. Along with 
physicians’ fear of inducing bleeding complications 
it results in reduced usage of anticoagulation 
therapy in older patients. A pragmatic approach 
based on a yes/no decision rather than a risk scoring 
stratification unless there is a contraindication for 
oral anticoagulation is suggested (3).
In univariate analysis, risks such as age ≥75 
years, history of cerebral ischemia, CHADS(2) score 
≥2 and TEE presence significantly correlate with 
IS incidence rate of patients with nonvalvular AF 
(NVAF) (45).
AH, hyperlipidemia and tobacco smoking are 
identified as risk factors of new vascular events by 
nearly 90% of 182 surviving primary care patients 
with previous IS or TIA while AF and diabetes 
mellitus are recognized by less than 50% of these 
patients (43). 
There are increased hazard ratios of IS among 
manual workers in Sweden occupationally exposed 
to small (<1 μm) as well as large particles (>1 μm) for 
≥5 years. The risks are higher for workers exposed 
for ≥5 years compared to ‘ever exposed’ participants 
indicating a dose-response relationship (42).
About one half of cases with IS can be prevented 
through control of modifiable risk factors and lifestyle 
changes. Recent clinical trials of new anticoagulants 
(factor Xa inhibitors and direct thrombin inhibitors) 
indicate alternative strategies in IS prevention for AF 
patients (17).
A systematic review of the evidence on 
the relationship between the individual clinical, 
echocardiographic and laboratory characteristics 
of AF patients and the risk of IS demonstrates the 
following good independent predictors of IS: a prior 
IS or TIA (15/16 positive studies, risk ratio (RR) 
2,86), AH (11/20 positive studies, RR 2,27), aging 
(9/13 positive studies, RR 1,46 per decade increase), 
structural heart disease (9/13 positive studies, RR 
2,0) and diabetes mellitus (9/14 positive studies, RR 
1,62) (33).
Among 1688 IS patients alive at three months, 
age, prestroke dependency, IS severity, and absence of 
comorbidities are statistically significantly associated 
with good functional outcome. In multivariate 
analysis, a higher probability of good outcome is 
observed in patients with college or university degree 
than in those with no completed education (23).
DRUG THERAPY
Initially, anticoagulation with the vitamin K 
antagonist warfarin represents the optimal drug for 
IS prevention in moderate- to high-risk AF patients. 
Aspirin exerts a more modest effect and reduces the 
risk of IS by a relative factor of 21% (38). 
Warfarin therapy is complicated by interactions 
with food and other drugs, variability in metabolism, 
a delayed onset of action and requirement for regular 
monitoring (10). Patients who are monitored by 
specialized anticoagulation clinics are out of the 
therapeutic range about 37% of the time, and warfarin 
patients monitored in community-based ones do 
49% of the time (6). Warfarin-associated hemorrhage 
results in a mortality of 42% with another 34% of 
patients suffering from major disability (20).
A total 1953 IS patients discontinue warfarin 
3-4 days before AF ablation (first group) and 1,327 
ones continue this therapy during the periprocedural 
period (second group). Symptomatic IS or TIA occur 
in 13 patients (0,67%) of the first group and in 2 
patients (0,15%) of the second one (p=0,021). Major 
hemorrhagic complications occur in 26 patients 
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(1,3%) of the first group and in 15 patients (1,1%) of 
the second one (p=0,80). The continued warfarin 
therapy could reduce IS incidence rate without 
increasing the hemorrhagic complications (27).
The Rochester Epidemiology Project Medical 
Linkage System is used to examine 100 acute IS 
patients with AF on warfarin treatment for secondary 
IS prevention from 1980 to 1994. Major bleeding 
events occur in 41 patients at a median of 19 months 
after warfarin initiation. Patients with a history 
of hemorrhage before warfarin treatment develop 
more commonly major hemorrhage (15% versus 3%; 
p=0,04) which indicates high lifetime bleeding risk 
associated with warfarin treatment (40).
The risk of IS due to the use of warfarin and 
aspirin is estimated in a population-based cohort 
study of all patients aged at least 18 years with a first-
ever diagnosis of chronic AF in 1993-2008 within 
the UK General Practice Research Database. IS is 
diagnosed in 5519 out of a total of 70766 AF patients. 
Warfarin provides a net clinical benefit maintained 
with longer duration of use within therapeutic range 
(5).
Some patients with AF and concomitant IS risk 
factors can be unsuitable for anticoagulation because 
of refusal to comply with regular international 
normalized ratio (INR) monitoring, fall risk or prior 
major hemorrhage due to an irreversible cause. The 
Atrial Fibrillation Clopidogrel Trial with Irbesartan 
for Prevention of Vascular Events compares aspirin 
with combined aspirin and clopidogrel in patients 
with AF judged to be warfarin ineligible (13). The 
combination therapy reduces by 0,9% the absolute 
risk of IS and increases the risk of major bleeding 
(2,0% versus 1,3%). Although this result suggests 
that the bleeding risks of combination therapy often 
outweigh its benefits, this therapy can be sufficient 
in patients who are already receiving it following a 
coronary intervention, are at a lower IS risk, or are 
warfarin ineligible (13).
A meta-analysis of 13 randomized trials 
comparing the combination of clopidogrel and 
aspirin versus aspirin alone and covering a total of 
90433 participants at a mean age 63 years shows that 
IS reduction by means of dual antiplatelet therapy by 
23%. Among 1930 participants with recent (<30 days) 
brain ischemia from four trials, IS reduces by 33% 
by using of clopidogrel plus aspirin when compared 
to aspirin alone. However, dual antiplatelet therapy 
enhances the risk of major bleeding by 40% (31).
Warfarin’s many disadvantages have prompted 
a search for oral anticoagulants that are more 
predictable in their anticoagulant effects, easier to 
administer and potentially safer. Other oral vitamin 
K antagonists are being explored, as well as two 
alternate classes of anticoagulants: direct thrombin 
inhibitors (DTIs) and factor Xa inhibitors. They have 
minimal drug and food interactions and require no 
dosage adjustments or hematologic monitoring. DTIs 
include ximelagatran and dabigatran, the first new 
anticoagulant to receive FDA approval. The earliest 
member of this class is ximelagatran. It is proven non-
inferior to dose-adjusted warfarin, with a similar 
rate of major bleeding with both treatments (2). Its 
hepatotoxicity causes its withdrawal prior to FDA 
review. Its value is proof of principle that a DTI could 
be at least as effective as warfarin in high-risk AF 
patients, without the logistic drawbacks of warfarin. 
Dabigatran does not require INR monitoring and 
can be considered more cost-effective than vitamin 
K antagonists for IS prevention of AF patients in 
Switzerland (34).
The RE-LY (Randomized Evaluation of Long-
Term Anticoagulant Therapy, Warfarin, Compared 
with Dabigatran) trial compares dabigatran with 
dose-adjusted warfarin in 18113 patients with NVAF 
concerning IS, hemorrhagic stroke and systemic 
embolism (12). 
Two doses of dabigatran are compared with 
warfarin and although the dose of dabigatran 
is double-blinded, assignment to warfarin or 
dabigatran is not blinded. Low-dose dabigatran (110 
mg BID) is non-inferior to warfarin for all stroke and 
systemic embolism (1,53% per year for dabigatran 
versus 1,69% per year for warfarin; p<0,001 for non-
inferiority). High-dose dabigatran (150 mg BID) is 
superior to warfarin (1,11% versus 1,69% per year; 
p<0,001 for superiority). Most benefits of high-
dose dabigatran over warfarin are for IS prevention, 
with a 36% relative risk (RR) reduction in favour 
of the former (p<0,001). Low-dose dabigatran 
demonstrates safety superior to that of warfarin, 
with significantly less major bleeding (2,71% 
versus 3.36% per year; p=0,03). The risk of major 
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intracranial and extracranial bleedings with high-
dose dabigatran is insignificantly lower than that 
with warfarin (3,11% versus 3,36% per year; p=0,31). 
Although all anticoagulant-associated bleeding has 
the potential to be life-threatening, anticoagulation-
associated hemorrhagic stroke carries a 76% risk of 
death or permanent disability and is the most feared 
complication of this therapy (20). 
Based on the results of the RE-LY trial, 
dabigatran (Pradaxa, Boehringer-Ingelheim) 
is approved by the FDA in October 2010 for IS 
prevention in NVAF patients at a dose of 150 mg BID 
in patients with creatinine clearance >30 mL/min 
and 75 mg BID in those with creatinine clearance 
between 15 and 30 mL/min. Even among patients 
with moderate renal impairment, the 150-mg dose 
of dabigatran is more effective than the 110-mg one 
as it diminishes IS incidence rate by almost half 
(1,3 versus 2,4 events/100 patient-years) while not 
increasing major bleeding incidence rate (5,3 versus 
5,7 events/100 patient-years) (7,49). The 110-mg dose 
is approved in most other countries, including those 
of Europe.
An analysis of RE-LY data concerning the 
bleeding risks associated with either dose of 
dabigatran indicates that extracranial bleeding rates 
increase with age and are comparable to or slightly 
higher than those with warfarin in patients aged over 
75 years. Intracranial bleeding rates are significantly 
lower than those with warfarin and are not affected 
by age (RR for 150 mg dabigatran compared to 
warfarin: 0,43 in patients under the age of 75 years 
and 0,42 in patients aged 75 years or more) (18). 
Dabigatran is more cost-effective than warfarin 
for patients at a high (CHADS2≥3) moderate 
(CHADS2≥2) risk for IS provided that the time in 
the therapeutic range is greater than 57,1% (41). It 
is not cost-effective for patients with a CHADS2=1, 
although another analysis (21) concludes otherwise, 
primarily due to methodological differences. Both 
analyses are conducted based on cost data in the USA 
and can’t be applicable in other countries.
Tecarfarin is a new oral vitamin K epoxide 
reductase antagonist (19). It is a structural 
analogue of warfarin, highly protein bound (99%) 
and metabolized by carboxyl esterases in liver 
microsomes. Its mechanism of action is identical to 
that of warfarin, although it differs substantially in 
that it is not metabolized by the CYP450 system. It 
offers the possibility of effective anticoagulation that 
can be monitored by INR, but with fewer CYP450-
mediated drug-drug and drug-food interactions. 
Two oral factor Xa inhibitors, rivaroxaban and 
apixaban, are investigated as alternatives to warfarin 
for IS prevention in high-risk AF patients. They 
present with potential advantages over warfarin 
similar to those of DTIs such as consistent dosing 
without significant food or drug interactions or 
the need for monitoring. The ROCKET-AF trial 
demonstrates that rivaroxaban is non-inferior 
to warfarin for the prevention of IS or systemic 
embolism. However, unlike dabigatran, rivaroxaban 
does not decrease the risk of IS. The overall risk of 
major and non-major clinically relevant bleeding is 
comparable, but there is a lower risk of intracranial 
and fatal bleeding in the rivaroxaban group (32).
Apixaban is compared to warfarin in the 
ARISTOTLE trial (Apixaban for the Prevention of 
Stroke in Subjects with Atrial Fibrillation) involving 
18201 patients with a mean CHADS2 of 2,1 and a 
median follow-up duration of 18 years. Patients are 
randomized to a twice daily dose of apixaban (5 mg) 
or warfarin titrated to an INR of 2,0-3,0. Apixaban 
is superior to warfarin for the prevention of IS and 
systemic embolism (hazard ratio = 0,79; p=0,01) and 
presents with a lower risk of bleeding (hazard ratio = 
0,69; p<0,001) (22).
Thrombolysis is administered for 31 out of 
698 cases (5%) with first-ever and recurrent cerebral 
infarction in Japan. Its rate is 16% of 197 cerebral 
infarction patients admitted within three hours of 
onset (25).
OCCLUSION DEVICES
Autopsy studies suggest that most cerebral 
emboli in patients with AF originate in the LAA. 
It is theoretically desirable to isolate the LAA from 
the circulation, presumably preventing embolism 
from this site, even after anticoagulation is ceased. 
The non-randomized continued access protocol 
registry for the Watchman device shows a lower 
complication rate such as pericardial effusion and 
suggests that greater operator experience decreases 
the rate of major complications (36). LAA exclusion 
protects against AF-related IS and other embolic 
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complications through different strategies such 
as surgical amputation or ligation, percutaneous 
endocardial occlusion by deployment of occlusive 
devices, and ligation of the LAA via a closed-chest, 
percutaneous, epicardial catheter-based approach in 
selected patients (4).
A second type of LAA occlusion device, the 
Amplatzer Cardiac Plug (AGA, Minneapolis, MN, 
USA) is implanted in patients with contraindications 
to warfarin in Asia and Europe. Postimplantation 
treatment is 1-3 months of clopidogrel and lifelong 
aspirin. Initial results from 19 patients in the Asia 
study show no residual leakage around the device 
and no cases of IS or systemic embolism at a mean 
follow-up of 12,7 months (28). 
Emergent stent-assisted endovascular carotid 
artery thrombolysis of IS due to acute cervical 
internal carotid artery occlusion results in excellent 
recanalization rates and favourable clinical outcomes 
as assessed by using NIHSS scores (15). Twenty 
patients undergo mechanical thrombectomy for 
large vessel occlusion by means of Merci (MER), 
Penumbra (PEN) or Solitaire-FR (SOL) procedures. 
Complete recanalization is achieved in 59,1% of the 
cases, i. e. in 40% - with MER, in 45,5% - with PEN, 
and in 100% - with SOL. The SOL device presents 
with a significantly higher rate of angiographic 
recanalization, requires a lesser number of passes 
and other associated than MER and PEN (1). SOL is 
used as the first-line device to restore blood flow in 
141 acute IS patients at a mean age of 66 years and 
median NIHSS score of 18. Of them, 74 patients 
have received intravenous tissue-type plasminogen 
activator before endovascular treatment. There is 
complete revascularization in 120 of 142 occlusion 
sites (85%) and good outcome in 77 of 141 patients 
(55%). The latter is more frequent in patients on this 
drug therapy (in 66% versus 42%; p<0,01) (16).
PREVENTION
A meta-analysis of eight cohort studies from 
the United States, Northern Europe, Australia, and 
Japan published between January 1990 and May 
2012 reveal that total dietary fiber intake is inversely 
associated with risk of first hemorrhagic stroke plus 
IS. However, soluble fiber intake (4 g/day) does not 
relate to IS risk reduction. Recent findings support 
dietary recommendations to increase intake of total 
dietary fiber (46).
Alternative IS prevention strategies could 
spare patients with infrequent or short-lived 
paroxysms of AF the risks and inconveniences 
of continuous anticoagulation. These strategies 
are examined in individuals with dual-chamber 
pacemakers, cardioverter-defibrillator and cardiac 
resynchronization therapy defibrillator devices. 
Current device technology allows for nearly real-
time continuous remote monitoring and thus 
patients with infrequent AF episodes may start and 
stop anticoagulation only around the time of an AF 
episode. 
A final strategy to prevent IS and to reduce the 
risk of this pathology in AF patients is to maintain 
them in sinus rhythm (‘rhythm control’). AF is 
asymptomatic, symptoms are unreliable measures 
of rhythm control in those patients who do have 
them, antiarrhythmic drugs are often unsuccessful 
at maintaining sinus rhythm. Symptomatic AF 
episodes can be converted into asymptomatic ones 
by drug or ablation therapy. There is rising interest 
in the possibility that newer approaches to AF 
treatment may provide sufficient rhythm control 
to allow the cessation of anticoagulation. Novel 
antiarrhythmic agents are associated with a reduced 
risk of IS (11). In the ‘A Trial with Dronedarone to 
Prevent Hospitalization or Death in Patients with 
Atrial Fibrillation’ study, dronedarone diminishes 
the risk of IS in AF patients. Potential mechanisms 
for this reduction include decreasing blood pressure 
and lowering heart rate. Although it is possible that 
the reduced IS incidence rate is due to the patients 
having better rhythm control, even patients who are 
commonly with AF exhibit this decreased rate (11). 
Patients with high-risk AF who can tolerate 
anticoagulation have three options for IS prevention. 
Warfarin, dabigatran and rivaroxaban each have 
individual risks and lifestyle benefits that must be 
considered with each patient. In some patients unable 
or unwilling to use anticoagulants indefinitely, 
the risk-benefit ratio may favour the combination 
of aspirin and clopidogrel, or percutaneous LAA 
occlusion, for better IS prevention than aspirin 
monotherapy. New cardiac monitoring technology 
offers clinicians the ability to detect AF and the usage 
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of selective anticoagulation. Such advances improve 
the outlook for preventing both first and recurrent 
IS in patients at risk for AF-related cerebrovascular 
disease.
Promising neuroprotection that meets the 
Stroke Academic Industry Roundtable criteria and 
is based on a more profound understanding of the 
complex IS pathophysiology such as inhibitors of 
NADPH oxidases and PSD-95, hypothermia and 
ebselen, a seleno-organic compound with glutathione 
peroxidase-like activity, is nowadays intensively 
evaluated (30).
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